Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine β-hydroxylase inhibitor

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 6, 1998, Pages 963-970

  Stanley, William C ^a,b   Lee, Keiho ^a   Johnson, Lowell G ^a   Whiting, Roger L ^a   Eglen, Richard M ^a   Hegde, Sharath S ^a  

^a ROCHE BIOSCIENCE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamines; Congestive heart failure; Dopamine; Dopamine hydroxylase; Hypertension; Norepinephrine; Sympathetic

Indexed keywords

DOPAMINE; DOPAMINE BETA MONOOXYGENASE; DOPAMINE BETA MONOOXYGENASE INHIBITOR; ENALAPRIL; NEPICASTAT; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOG; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE; TELEMETRY; VASCULAR RESISTANCE;

ANIMALS; CARDIOVASCULAR SYSTEM; DOGS; DOPAMINE BETA-HYDROXYLASE; ELECTRIC STIMULATION; ENALAPRIL; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; IMIDAZOLES; KIDNEY; MALE; RATS; RATS, INBRED SHR; THIONES; TYRAMINE;

EID: 0031801398     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199806000-00023     Document Type: Article

References (40)

1. Esler M, Jennings G, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3-20.
2. Packer M. Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with β-adrenergic agonists and antagonists. J Cardiovasc Pharmacol 1989;14:S38-43.
3. Cohn JN, Levine BT, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
4. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;871(suppl VI):VI40-8.
5. Davis D, Bailey R, Zelis R. Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol 1988;254:E760-6.
6. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardio-renal sympathetic nervous activity. Circulation 1986;73:615-21.
7. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23:570-8.
8. Meredith IT, Broughton A, Jennings GL, Esler MD, Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618-24.
9. Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure volume overload. J Clin Invest 1985;76:1740-7.
10. Leimbach WN, Wallin BG, Victor RG, Aylward RE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-9.
11. Benedict CR, Shelton B, Johnston DE, et al. for the SOLVD investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.
12. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985;17:291-306.
13. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994;75:105-13.
14. Hash TW, Prisant LW. β-Blocker use in systolic heart failure and dilated cardiomyopathy. J Clin Pharmacol 1997;37:7-19.
15. Bristow MR, Gilber EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
16. Sabbah H, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
17. Berkowitz BA, Ohlstein EH. Stimulation of vascular dopamine receptors: status and future strategies. Clin Exp Hypertens 1987;A9:1037-44.
18. Berkowitz BA, Arleth AJ, Sung CP, Kruse LI, DeWolf WE, Ohlstein EH. Effects of the novel dopamine β-hydroxylase inhibitor SK&F 102698 on catecholamines and blood pressure in spontaneously hypertensive rats. J Pharmacol Exp Ther 1988;245:850-7.
19. Claxton IM, Palfreyman MG, Poyser RH, Whiting RL. BRL8242 (2[2-benximidazolyl)-amino-2-imidazoline dihydrochloride), a new inhibitor of dopamine-β-hydroxylase with antihypertensive activity. Eur J Pharmacol 1976;37:179-88.
20. Corrodi H, Fuxe K, Hamberger B, Ljungdahl A. Studies on central and peripheral noradrenaline neurons using a new dopamine-β-hydroxylase inhibitor. Eur J Pharmacol 1970;12:145-55.
21. Fuller RW, Snoddy HE, Perry KW. Dopamine accumulation after dopamine beta-hydroxylase inhibition in rat heart as an index of norepinephrine turnover. Life Sci 1982;31:563-79.
22. Hellstrom E, Tottmar O. Implantation of disulfiram in rats. Pharmacol Biochem Behav 1980;13(suppl 1):73-82.
23. Inoue M, Kurahashi K, Fujiwara M. Noradrenaline turnover after left coronary artery ligation in rat heart. Eur J Pharmacol 1987;143:251-7.
24. Ishii Y, Mimura C, Homma M. Effect of dopamine-β-hydroxylase inhibitors on blood pressure and cardiac norepinephrine levels in rats subjected to immobilization stress. J Pharmacol Exp Ther 1976;198:589-95.
25. Korduba CA, Veals J, Wohl A, Symchowicz S, Tabachnick IIA. SCH 10595, an effective dopamine β-hydroxylase inhibitor and a hypotensive agent. J Pharmacol Exp Ther 1973;184:671-7.
26. Matta RJ, Wooten FG. Pharmacology of fusaric acid in man. Clin Pharmacol Ther 1973;14:541-6.
27. Ohlstein EH, Kruse LI, Ezekiel M, et al. Cardiovascular effects of a new potent dopamine β-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 1987;241:554-9.
28. Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1986;333:219-23.
29. Terasawa F, Hidaka H. Time-course changes in blood pressure, urinary excretion of norepinephrine and dopamine after administration of fusaric acid in a single dose in elderly hypertensive patients. Jpn Circ J 1976;40:785-91.
30. Gellai M, DeWolf RE, Ruffolo RR Jr. Effect of dopamine β-hydroxylase inhibition on systemic hemodynamics in conscious, spontaneously hypertensive rats. Pharmacology 1990;41:82-90.
31. Terasawa F, Ying LH, Kameyama M. The hypotensive effect of fusaric acid: the results of long-term administration of fusaric acid in elderly hypertensive patients. Jpn Circ J 1976;40:1017-791.
32. Velasco M, Gilbert CA, Rutledge CO, McNay JL. Antihypertensive effect of a dopamine beta-hydroxylase inhibitor, bupicomide: a comparison with hydralazine. Clin Pharmacol Ther 1975;18:145-53.
33. Stanley WC, Li B, Bonhaus D, et al. Catecholamine modulatory effects of nepicastat (RS 25560-197), a novel, potent and selective inhibitor of dopamine β-hydroxylase. Br J Pharmacol 1997;121: 1803-9.
34. Gillespie JS, Muir TS. A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Br J Pharmacol 1967;30:78-87.
35. Baum T. Fundamental principles governing regulation of circulatory function. In: Antonaccio M, ed. Cardiovascular pharmacology. New York: Raven Press, 1990:1-36.
36. Spector S, Tarver J, Berkowitz BA. Catecholamine biosynthesis and metabolism in the vasculature of normotensive and hypertensive rats. In: Okomoto K, ed. Spontaneous hypertension. New York: Springer-Verlag, 1972:41-5.
37. Strein K, Sponer G, Muller-Beckmann B, Bartsch W. Pharmacological profile of carvedilol, a compound with β-blocking and vasodilating properties. J Cardiovasc Pharmacol 1987;10(suppl 11):S33-41.
38. Lokhandwala MF, De Feo ML, Cavero I. Physiological and pharmacological significance of dopamine receptors in the cardiovascular system. Prog Hypertens 1988;1:115-44.
39. Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA III, Biaggioni I. Dopamine beta-hydroxylase deficiency: a genetic disorder of cardiovascular regulation. Hypertension 1991;18:1-8.
40. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure. N Engl J Med 1996;334:1396-7.